KAYIHAN OĞUZ KARAMUSTAFALIOĞLU, Nesrin DİLBAZ, Ali ÇAYKÖYLÜ, Tunç ALKIN, ALİ SAFFET GÖNÜL, MURAD ATMACA

Major depresif bozukluk tedavisinde uzatılmış salımlı trazodon

Majör depresif bozukluk (MDB) sık görülen bir psikiyatrik bozukluktur. Tedavinin amacı belirtilerde remisyon ile günlük işlevlerin düzelmesidir ve antidepresanlar, majör depresif bir nöbetin (orta-şiddetli depresif nöbet) ilk sırada gelen tedavileridir. Bu makale uzatılmış salımlı trazodonun (TzCOAD) farmakolojik özelliklerini, MDB’deki klinik etkinliği ve güvenliğini incelemektedir. Uzman görüşü: Günde tek doz TzCOAD, hızlı salımlı trazodon (TzIR) ve diğer antidepresanlara benzer bir etkinlik ve artmış tolerabilite sağlayabilir. (Anadolu Psikiyatri Derg 2019; 20(5):453-459)

Extended-release trazodone in the treatment of major depressive disorder

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants. (Anatolian Journal of Psychiatry 2019; 20(5):453-459)

PDF

___

World Health Organization. Depression. Available at: https://www.who.int/news-room/fact-sheets/ detail/ depression. (Accessed March, 7 th 2019)
Goracci A, Forgione RN, De Giorgi R, Coluccia A, Cuomo A, Fagiolini A. Practical guidance for prescribing trazodone extended-release in major depression. Expert Opin Pharmacother 2016; 17(3):433-441.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. The potential role of Marginal Structural Models (MSMs) in testing the effect- tiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. World J Biol Psychiatry 2013; 14:334- 385.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and Longer-Term Outcomes in Depressed Outpa- tients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 2006; 163(11):1905-1917.
Fuller MA, Sajatovic M, Handiwala L. Clinical perspectives on the influence of drug formulation on patient tolerability and use of commonly pre- scribed antidepressants in major depressive dis- order. Arch Pharma Pract 2013; 4:83-92.
Fagiolini A, Comandini A, Dell’Osso MC, Kasper S. Erratum to: Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012; 26:1033-1049.
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14(10):536-546.
Karhu D, Gossen ER, Mostert A, Cronjé T, Fradette C. Safety, tolerability, and pharmaco- kinetics of once-daily trazodone extended-release caplets in healthy subjects. Int J Clin Pharmacol Ther 2011; 49(12):730-743.
Hidalgo RB, Sheehan DV. Trazodone extended release for major depressive disorder. Current Psychiatry 2010; 9(12):76-84.
Beasley CM Jr, Dornseif BE, Pultz JA, Bosom- worth JC, Sayler ME. Fluoxetine versus trazo- done: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52:294-299.
Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006; 22:1703-1713.
Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005; 21:1139-1146.
Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brullé C, Bouchard S, Rozova A. Extended- release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont) 2009 May; 6(5):20- 33.
Sheehan DV1, Rozova A, Gossen ER, Gibertini M. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull 2009; 42(4):5-22.
Češková E, Šedová M, Kellnerová R, Starobová O. Once-a-day trazodone in the treatment of depression in routine clinical practice. Pharma- cology 2018; 102:206-212.